Skip to main content

Table 2 Factors associated with failure to complete 12 weeks on study

From: Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases

  

Did not complete week 12

Completed week 12

p-value

N

 

7

23

 

CTx

Median (IQR)

656 (492, 811)

141 (88, 229)

0.002

BSAP

Median (IQR)

44 (26, 68)

15 (14, 22)

0.005

TGF-β, ng/ml

Median (IQR)

26.3 (16.8, 30.7)

20.7 (17.1, 25.5)

0.38

Activin-A, pg/ml

Median (IQR)

2922 (1666, 9576)

517 (404, 775)

<0.001

NTx

Median (IQR)

NA

158 (73, 282)

-

P1NP

Median (IQR)

123075 (80014, 178930)

54334 (36692, 77623)

0.002

BSP

Median (IQR)

63.9 (55.3, 90.4)

15.9 (8.2, 32.9)

0.004

FACT-BP

Median (IQR)

15 (7, 36)

12 (5, 23)

0.37

BPI

Median (IQR)

57 (12, 65)

6 (0, 29)

0.049

# of SRE, pre , study (n = 25)

0

1

10

 

1

0

9

 

2

1

4

 

# of SRE , on or post, study (n = 25)

0

2

16

 

1

0

3

 

2

0

3

 

3

0

1

 

Duration of bone mets, in months

Median (IQR)

28 (18, 41)

18 (12, 29)

0.19

Time from primary to bone mets (n = 25)

<2 years

1

12

 

2–5 years

0

5

 
 

>5 years

1

6

Â